Inoperable stage III non-small cell lung cancer
Conditions
Interventions
1:Endo combined with radiotherapy and chemotherapy on the 1st, 3rd, 5th and 7th week: Endostar: 7.5 mg / m2 / d × 7 days, continuous intravenous infusion, IMRT 6 to 7 weeks after the second week Stron
Sponsors
Affiliated hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years male and female; 2. The pathology / cytology was confirmed as non-small cell lung cancer, and the UICC 8th edition of TNM was stage III NSCLC inoperable; 3. Karnofsky score =70 points or ECOG 0-1 points; 4. Pulmonary function: FEV1> 50%, mild to moderate lung function impaired; 5. Evaluation criteria of solid tumor efficacy (RECIST1.1) measurable lesions; 6. blood: white blood cells = 4.0 × 10^9/L, neutrophils =2.0×10^9/L, platelets =100×10^9/L, hemoglobin =100g/L; 7. Blood biochemistry: Serum creatinine = 1.25 times upper limit of normal (ULN), serum creatinine clearance =60 mL/min, serum bilirubin = 1.5×ULN, AST and ALT <2.5×ULN, alkaline phosphatase = 5×ULN; 8. The first treatment for this treatment (no history of chest radiotherapy; no history of concurrent chemoradiation); 9. voluntarily joined the trial, signed informed consent, good compliance, with follow-up.
Exclusion criteria
Exclusion criteria: (1) lung carcinoid tumor or small cell lung cancer; (2) history of other malignant diseases, contraindications to radiotherapy and chemotherapy (important organ insufficiency, severe infection, unstable angina, heart failure, uncontrolled arrhythmia, valvular heart disease, malignant chest cavity within 6 months after myocardial infarction And / or pericardial effusion; (3) thrombosis or bleeding events (including hemoptysis, gastrointestinal bleeding, hematemesis, CNS bleeding, epistaxis, vaginal bleeding, cerebral infarction and transient ischemic attack) at 6 months; (4) active gastroduodenal ulcer, abdominal fistula and non-gastrointestinal fistula, gastrointestinal perforation or abdominal abscess occurred in June; (5) Previous NSCLC chemotherapy or chest irradiation, or any monoclonal antibody or small molecule inhibitor of VEGF / VEGFR treatment; (6) Patients who require permanent oral anticoagulants (such as warfarin, rivaroxaban, dabigatran, coumarin acetate, etc.); (7) stable antihypertensive treatment, poor blood pressure control or resting blood pressure> 150 / 100mmHg; (8) The presence of human immunodeficiency virus (HIV) infection, syphilis or active tuberculosis infection; (9) lesions can not be clearly identified or measured on CT; (10) Past allergy to biological agents; (11) pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progressive survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total survival;Objective response rate;Local progression-free survival;The incidence of toxic reactions; | — |
Contacts
Public ContactYu-Ju Bai
Affiliated hospital of Zunyi Medical University
Outcome results
None listed